Whitehawk Therapeutics Inc. has released a corporate presentation detailing its differentiated antibody-drug conjugate $(ADC)$ platform, which features three ADC assets licensed from WuXi Biologics and novel linker-payload technology from Hangzhou DAC. The company highlights the use of a proprietary topoisomerase 1 (TOP1) inhibitor with an optimized DAR6 configuration, carbon bridge cleavable linker, and Fc-attenuated antibodies to enhance tumor targeting and minimize toxicity. Preclinical data indicate that the Whitehawk ADC platform demonstrates increased potency, improved stability, and a higher safety margin compared to average TOP1 inhibitor ADCs, with 3-10 times greater potency, 5-25 times more stability, and a 2-3 times higher safety margin in animal models. The portfolio includes three main assets: HWK-007 targeting PTK7 for a range of solid tumors, HWK-016 targeting MUC16 with an IND submitted, and HWK-206 targeting SEZ6 in neuroendocrine and CNS tumors, with anticipated clinical development milestones. The company reports a cash balance of $162.6 million as of September 30, 2025, with an expected runway into 2028, supporting ongoing clinical programs. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein.